Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes

G Daniel Brooks
The Asthma and Allergy Center, Bellevue, NE, USA

Abstract: Uncontrolled asthma continues to be a problem for many patients with moderate-to-severe allergic asthma. Dupilumab, which blocks the receptors for interleukin-4 and interleukin-13, has been effective in reducing asthma exacerbations, improving forced expiratory volume in one second (FEV1), and reducing oral corticosteroid use. When selecting patients for dupilumab, it is important to consider entry criteria for the original studies, subgroups that have responded best, and the presence of comorbid diseases that may also respond to dupilumab. Factors that were considered when selecting patients likely to respond to dupilumab in asthma studies include: failure of moderate or high dose inhaled steroids in combination with an additional controller medication, baseline FEV1 reversibility of 12% or greater, and Asthma Control Questionnaire > 1.5. The baseline characteristics that predicted a better response to dupilumab included blood eosinophils > 150 cells/mm3 and fractional exhaled nitric oxide > 25 parts per billion. Comorbidities that may also respond to treatment with dupilumab include atopic dermatitis, chronic rhinosinusitis, and allergic rhinitis. A combination of these factors should be considered when selecting the patients most likely to benefit from dupilumab.

Keywords: allergic asthma, dupilumab, eosinophils, nitric oxide, comorbidity

Allergic Inflammation in Asthma
A significant proportion of patients with moderate-to-severe asthma continue to have poor control of asthma symptoms and develop exacerbations despite treatment with combination controller medications, including high doses of inhaled steroids.1 About half of patients with severe asthma will have allergic airway inflammation that is refractory to treatment with inhaled steroids.2

Allergic inflammation in asthma is characterized by cytokines produced by T helper, type 2 cells (Th2 cells).3 Th2 cells secrete interleukin (IL)-4, IL-5, and IL-13. IL-4 promotes the differentiation of additional Th2 cells. The Th2 cells migrate to the airway and secrete more IL-4, IL-5 and IL-13. IL-5 promotes eosinophil maturation, activation and survival. IL-13 in the airway promotes immunoglobulin E (IgE) synthesis, mucus hyper-secretion, goblet cell hyperplasia, fibrosis and airway hyper-responsiveness. See Figure 1.

The receptors for IL-4 and IL-13 have one protein in common, the IL-4 receptor alpha subunit. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor alpha subunit. By targeting the common subunit, it blocks the actions of both IL-4 and IL-13. Dupilumab has been approved by the United States Food and Drug Administration (FDA) for use in asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis. This...
review examines the characteristics of patients that predict better outcomes in addition to the consideration of comorbid conditions that help determine patient selection for dupilumab.  

Alternative biologic therapies, which target mediators of Th2 inflammation, have also been FDA approved for the treatment of severe asthma. Omalizumab (anti–IgE), mepolizumab (anti–IL-5), reslizumab (anti–IL-5), and benralizumab (anti–IL-5 receptor) are all safe and effective in patients with severe asthma. There are no studies with a direct comparison of these drugs to dupilumab, so they will not be compared further. The purpose of this review is to provide an in depth summary of factors that would affect patient selection for dupilumab and serve as a single reference for applicable studies.

The FDA approved asthma indications of dupilumab are for “add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma.” The evidence to support these indications includes two Phase 3 studies of uncontrolled moderate-to-severe asthma and one phase 3 study of steroid dependent asthma.  

One of the considerations when using dupilumab should be the basic characteristics of the asthma for patients who entered these studies. See Table 1.

**How Patients Were Selected for Dupilumab Studies**

**Moderate-to-Severe Asthma**

Most of the patients studied on dupilumab had two different measures of poor asthma control despite treatment with moderate or high dose inhaled steroids in combination with an additional controller medication. The trials of dupilumab in moderate-to-severe asthma enrolled patients age 12 and older. In order to qualify for the trial, the patients had to be uncontrolled on a total daily dose of 500 μg fluticasone propionate or greater. Patients also had

**Table 1** Inclusion Characteristics of Patients in Dupilumab Studies

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Failing &gt; 500 μg of fluticasone propionate</td>
<td>Inclusion criterion for all of the phase 3 asthma trials</td>
</tr>
<tr>
<td>Failing an additional controller medication</td>
<td>Inclusion criterion for all of the phase 3 asthma trials</td>
</tr>
<tr>
<td>12% reversibility in FEV₁ at baseline</td>
<td>Inclusion criterion for moderate-to-severe trials</td>
</tr>
<tr>
<td>Asthma Control Questionnaire &gt; 1.5</td>
<td>Inclusion criterion for moderate-to-severe trials</td>
</tr>
<tr>
<td>Oral glucocorticoid dependent asthma</td>
<td>Inclusion criteria for severe steroid dependent trial</td>
</tr>
</tbody>
</table>

**Abbreviation:** FEV₁, forced expiratory volume in one second.
to be taking up to two additional controller medications (typically a long acting beta-agonist, though other controllers were permitted). Qualifying characteristics of poor control included both baseline FEV<sub>1</sub> reversibility of 12% or more and Asthma Control Questionnaire (ACQ-5) of 1.5 or higher. The subjects also had one exacerbation in the last year defined by hospitalization, emergency room visit, or oral steroid burst of at least three days. The FEV<sub>1</sub> reversibility is a limitation because in clinical practice, a significant number of patients only have FEV<sub>1</sub> reversibility when they have asthma triggers or exacerbations. These patients were not represented in the trial.

Within these phase 3 trials, patients were randomly assigned in a 2:2:1:1 ratio to subcutaneous dupilumab 200 mg (400 mg loading dose), dupilumab 300 mg (600 mg loading dose), or to one of two separate placebo groups that matched volumes to the treatment groups. Treatment was given for 52 weeks. The design included a stepwise examination of primary endpoints. The first primary endpoint specified was the number of severe asthma exacerbations per patient-year during the 52 week time period. The second primary endpoint was the change in absolute FEV<sub>1</sub> value from baseline at week 12.

Overall, subjects in the study had a lower rate of asthma exacerbations for both doses studied. The rate of annualized severe exacerbations was 0.46 versus 0.87 for the 200 mg dupilumab group and matching control (47% lower, p<0.001). The rate was 0.52 versus 0.97 for the 300 mg dupilumab group and matching control (46% lower, p<0.001). The FEV<sub>1</sub> also improved 0.14 liters versus placebo for the lower dose (p<0.001) and 0.13 liters versus placebo for the higher dose (p<0.001).

**Table 2** Baseline Characteristics Favoring Response in Dupilumab Studies

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>Rationale</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood eosinophil count &gt; 300 cells/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Greatest reduction in asthma exacerbations happened in this cohort</td>
<td>Elevations of eosinophil count above 3000 cells/mm&lt;sup&gt;3&lt;/sup&gt; in 1.2% of patients on dupilumab</td>
</tr>
<tr>
<td>Blood eosinophil count &gt; 150 cells/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Asthma exacerbations and FEV&lt;sub&gt;1&lt;/sub&gt; were not better than placebo with eosinophils &lt; 150 cells/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>FE&lt;sub&gt;NO&lt;/sub&gt; &gt; 25 ppb</td>
<td>Asthma exacerbations and FEV&lt;sub&gt;1&lt;/sub&gt; were not better than placebo with lower FE&lt;sub&gt;NO&lt;/sub&gt;</td>
<td></td>
</tr>
</tbody>
</table>

**Patient Characteristics Favoring Response to Dupilumab**

Specific subgroups were declared prior to the study in moderate-to-severe asthma. Patients were stratified for separate analyses by blood eosinophil count and fraction of exhaled nitric oxide (FE<sub>NO</sub>). See Table 2. The patients were placed into three groups based on the presence of low blood eosinophil count (< 150 cells/mm<sup>3</sup>), moderate
did not have significant improvement. Subjects received 600 mg dupilumab measurement. Subjects with improvement in response to dupilumab demonstrated a 0.21 improvement in FEV1 versus placebo. The lower eosinophil group also predicted a statistically significant improvement.

The study of severe, steroid-dependent asthma performed an analysis of the same three blood eosinophil groups. It might be expected that blood eosinophils would be suppressed at baseline by the oral steroids, but elevated baseline blood eosinophils were relatively common within the study. Only 60 subjects had blood eosinophils < 150 cells/mm³ compared to 150 subjects with blood eosinophils >150 cells/mm³. Of these patients, 89 subjects had blood eosinophils > 300 cells/mm³. The patients with blood eosinophils > 300 cells/mm³ experienced a greater reduction in steroids relative to placebo. In contrast to the other study, subjects in this low eosinophil group still demonstrated a significant reduction in oral steroid dose relative to placebo.

In a separate analysis, the subjects were divided into pre-specified groups by FE_{NO} measurement. Subjects with elevated baseline FE_{NO} > 25 parts per billion (ppb) had a significant reduction in exacerbations with both doses of medication studied. Subjects with FE_{NO} < 25 ppb did not have a statistically significant reduction in asthma exacerbations. The FE_{NO} groups were also analyzed for FEV1 outcomes. The FE_{NO} > 25 ppb group also predicted FEV1 improvement in response to dupilumab.

A subgroup of allergic asthma patients was studied in a post-hoc analysis. Allergic asthma was defined by the presence of total IgE >30 IU/mL and detectable serum IgE to at least one perennial aeroallergen. The allergens tested included dust mites, Alternaria, Cladosporium, Aspergillus, cat, dog, and cockroach. Using these criteria, 1083 patients were assigned to the allergic asthma group. The allergic asthma group responded to dupilumab 200/300 mg with a significant decrease in severe exacerbations (37%/46% respectively). The other asthma group had a similar improvement.

In a different post-hoc analysis of the phase 2b data, subjects were separated into groups by the baseline frequency of asthma exacerbations. All groups demonstrated a statistically significant reduction in exacerbations. The treatment effect was greater in the patients with a history of the most exacerbations. These patients had more exacerbations in the placebo group.

**Comorbid Conditions to Consider**

There are several comorbid diseases that may influence the selection of patients for dupilumab. See Table 3. Atopic dermatitis, chronic rhinosinusitis, and allergic rhinitis may all have symptom improvement with the usage of dupilumab. Meanwhile, concurrent hypereosinophilic syndromes warrant caution.

**Atopic Dermatitis**

Patients with comorbid atopic dermatitis may have a significant improvement in their skin symptoms when treated with dupilumab. Before dupilumab was approved for asthma, it was approved for atopic dermatitis. Three trials of dupilumab were performed in patients with moderate-to-severe atopic dermatitis not controlled by topical corticosteroids. Subjects received 600 mg dupilumab

<table>
<thead>
<tr>
<th>Comorbid Disease</th>
<th>Rationale</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic dermatitis</td>
<td>35–40% of patients had significant improvement in symptoms of pruritus</td>
<td>Conjunctival or other eye side effects appeared more often in studies of atopic dermatitis</td>
</tr>
<tr>
<td>Chronic rhinosinusitis with nasal polyps</td>
<td>Nasal polyps reduced in size and nasal symptom scores improved</td>
<td>FEV1 and asthma control improved in these patients</td>
</tr>
<tr>
<td>Allergic rhinitis</td>
<td>Allergic rhinitis symptoms improved</td>
<td>Studies were from post-hoc analyses</td>
</tr>
<tr>
<td>Hypereosinophilic syndrome</td>
<td>Eosinophils were increased during treatment</td>
<td>Severe adverse event of worsening chronic eosinophilic pneumonia reported</td>
</tr>
</tbody>
</table>

Abbreviation: FEV1, forced expiratory volume in one second.
initial dose followed by 300 mg of dupilumab every two weeks or placebo. Reduction in itch score of four points was defined as a clinically significant response. In the first two, 16 week, studies 36% and 41% achieved this reduction in itch with dupilumab, compared to 9.5% and 12.3% with placebo. In the third study, 36% of people maintained their response at 52 weeks. This was a mixture of people who responded at 16 weeks and people who responded late. Of note, individuals in the atopic dermatitis trials were more likely to have conjunctivitis, blepharitis, keratitis, and eye pruritus on dupilumab than placebo. This side effect was not statistically significant in studies of asthma, so it appears to be more likely to happen in patients with atopic dermatitis.

**Chronic Rhinosinusitis with Nasal Polyposis**

Bachert et al first reported that chronic sinusitis and nasal polyps responded to dupilumab in a study of 60 patients. Patients were randomized to either dupilumab 300 mg (600 mg loading dose) or placebo. The primary endpoint was endoscopic nasal polyp score at 16 weeks, which was significantly lower in the dupilumab treatment group (p<0.001). Significant improvements in the computed tomography scan of the sinus, the SinoNasal Outcome Test (SNOT-22), and sense of smell were also reported as secondary endpoints. A subsequent subgroup analysis was performed on 35 subjects with asthma. Within this group, dupilumab was associated with improved asthma control and quality of life.

The rationale for prescribing dupilumab to patients with nasal polyps was strengthened in June of 2019, when the FDA gave approval for the use of dupilumab in patients who have chronic rhinosinusitis with nasal polyposis (CRSwNP). The basis of this approval was the outcome of two randomized, double-blind, placebo-controlled studies. The studies included subjects with CRSwNP who were refractory or intolerant of surgery or nasal steroids in the previous two years. The first study had 276 subjects who were randomized to receive either 300 mg of dupilumab or placebo every other week for 24 weeks. Dupilumab treatment resulted in improved endoscopic nasal polyp scores and nasal congestion symptoms scores. It was also associated with significantly less need for systemic steroids or surgery. In patients with comorbid asthma, it was associated with improved FEV₁ and asthma control.

The second study had 448 subjects randomized to 300 mg of dupilumab every other week for 52 weeks, 300 mg of dupilumab every other week for 24 weeks, followed by every four weeks until week 52, or placebo. The nasal polyp endoscopic score, nasal congestion symptom score, and need for systemic steroids or polyp surgery were all reduced. Patients with asthma again had improved FEV₁ and asthma control.

**Chronic Rhinosinusitis**

The phase 3 moderate-severe asthma study data was later analyzed to examine whether patients with self-reported chronic rhinosinusitis symptoms were more likely to have an improvement in their asthma outcomes. A significant limitation of the study was that data on nasal polyposis had not been collected. Patients with chronic rhinosinusitis generally had higher blood eosinophils and FENO at baseline but lower rates of allergic sensitization. During the study, chronic rhinosinusitis patients assigned to placebo had a greater number of severe asthma exacerbations than the placebo treated patients without chronic rhinosinusitis. Both groups had a statistically significant decrease in severe exacerbations. The decrease attributed to dupilumab was greater in the chronic rhinosinusitis group (61%) than in the other group (40%).

**Allergic Rhinitis**

Post hoc analyses of patients have found that allergic rhinitis symptoms improved while on dupilumab and that asthma improved in the subset of patients with allergic rhinitis. Weinstein analyzed the effect of dupilumab on nasal symptom scores in a post-hoc analysis of a phase 2b trial. Perennial allergic rhinitis was determined by the presence of detectable serum IgE to Aspergillus, cat, dog, dust mite, German cockroach or Oriental cockroach. Patients with nasal polyps were excluded. Nasal symptoms were measured using the Sino-Nasal Outcome Test (SNOT-22) after 24 weeks. Blinded, randomized 1:1:1:1 assignment of groups was to dupilumab 200 mg every 2 weeks, dupilumab 300 mg every two weeks, dupilumab 300 mg every 4 weeks, or placebo. The allergic rhinitis group treated with 300 mg dupilumab every two weeks had a significant improvement in the SNOT-22 score compared to the placebo group. This included statistically significant improvements in nasal congestion, rhinorrhea, sneezing and postnasal drainage. The 200 mg dupilumab group also had better scores than placebo but this was not statistically significant. Study subjects without allergic rhinitis did not have significant response in SNOT-22. Within this study, FEV₁ improved in patients with allergic rhinitis treated with 300 mg dupilumab and patients without allergic rhinitis treated with 200 mg.
of this taper, even though it varies slightly from the studied protocol. It is important to educate patients who are tapering steroids regarding symptoms of poor asthma control and the need to contact their physician.

Because of the role of Th2 immunity in helminth parasitic defense, any helminth infection should be treated before the initiation of dupilumab. If a patient does contract a helminth while on dupilumab, and fails to respond to treatment, dupilumab should be stopped until the infection resolves.

Urticaria, rash, erythema nodosum, serum sickness and anaphylaxis have occurred after dupilumab administration. These are contraindications to further use.

Conclusions
A significant proportion of patients with asthma are not controlled with inhaled steroids. The IL-4 receptor alpha blocker, dupilumab, is efficacious in patients with uncontrolled moderate-to-severe asthma. Patients were selected into the original studies based on FEV1 reversibility at baseline and an asthma control questionnaire that indicated poor control. Subsequent analysis demonstrated that important predictors of response to dupilumab include blood eosinophil count greater than 150 cells/mm³ and FEV1SO greater than 25 ppb. Another factor favoring the choice of the dupilumab is the presence of responsive comorbid diseases, including atopic dermatitis, chronic rhinosinusitis with nasal polyposis and allergic rhinitis. Dupilumab is an effective asthma medication for well selected patients not responding to inhaled steroids.

Disclosure
The Asthma and Allergy Center, employer of Dr. Brooks, has received payment for the conduct of multiple clinical trials from Sanofi, AstraZeneca, GlaxoSmithKline, Novartis, and Teva. The author reports no other conflicts of interest in this work.

References